Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 4/20 | 0.51 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.40 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.33 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.33 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1572199 | 0.77 | HTR4 (0.50) | HTR4 | |
| SCHEMBL1339676 | 0.76 | TSHR (0.55) | TSHRHTTBAZ2BALDH1A1GAA | |
| SCHEMBL1572027 | 0.68 | TSHR (0.47) | TSHRHTTBAZ2BALDH1A1GAA | |
| SCHEMBL1572026 | 0.68 | TSHR (0.47) | TSHRHTTBAZ2BALDH1A1GAA | |
| SCHEMBL1571881 | 0.68 | TSHR (0.47) | TSHRHTTBAZ2BALDH1A1GAA | |
| SCHEMBL1339780 | 0.67 | TSHR (0.46) | TSHRHTTBAZ2BALDH1A1GAA | |
| SCHEMBL3372732 | 0.66 | BAZ2B (0.58) | TSHRHTTBAZ2BALDH1A1GAA | |
| SCHEMBL26844606 | 0.66 | BAZ2B (0.61) | TSHRHTTBAZ2BALDH1A1GAA | |
| SCHEMBL1341232 | 0.65 | BAZ2B (0.65) | TSHRHTTBAZ2BALDH1A1GAA | |
| SCHEMBL15778667 | 0.64 | NPSR1 (0.73) | TSHRHTTBAZ2BALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110124636-A1 | 2-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-05-26 | — | — | US | disclosed |
| EP-2094690-B1 | 2-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-04-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124636-A1 | 2-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, CNR1 | TSHR 515/4885HTT 884/4885BAZ2B 610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.